Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Outset Medical, Inc. Director's Dealing 2021

Sep 16, 2021

33476_dirs_2021-09-16_bebe8918-6427-406f-9b21-f3b59957b5d4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Outset Medical, Inc. (OM)
CIK: 0001484612
Period of Report: 2021-09-15

Reporting Person: Brottem John L. (General Counsel)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-09-15 Common Stock M 3500 $9.48 Acquired 18547 Direct
2021-09-15 Common Stock S 3500 $50.3086 Disposed 15047 Direct
2021-09-15 Common Stock M 1445 $9.48 Acquired 16492 Direct
2021-09-15 Common Stock S 1445 $50.4443 Disposed 15047 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-09-15 Non-Qualified Stock Option (right to buy) $9.48 M 1445 Disposed 2030-05-26 Common Stock (1445) Direct
2021-09-15 Performance Options (right to buy) $9.48 M 3500 Disposed 2030-05-26 Common Stock (3500) Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 14, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $49.92 to $50.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $50.01 to $50.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold within the range set forth in this footnote.

F4: This option vests 25% on May 26, 2021 and then in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

F5: This option vests if and to the extent that (i) the sum of (A) the 30-day closing price trading average of one Share of common stock of the Issuer ("Share") and (B) the Aggregate Cash Distributions is equal to or greater than $19.12 on any day following the expiration of the post-offering lockup period or (ii) the sum of (X) the value of all consideration that is distributable with respect to one Share in connection with a Corporate Event and (Y) the Aggregate Cash Distributions is equal to or greater than $20.86 as of the effective date of such Corporate Event.